tiprankstipranks
Elevance Health (ELV)
NYSE:ELV
US Market
ELV
Elevance Health
RESEARCH TOOLSreports
Want to see ELV full AI Analyst Report?

Elevance Health (ELV) Stock Forecast & Price Target

2,893 Followers
See the Price Targets and Ratings of:

ELV Analyst Ratings

Moderate Buy
16Ratings
Moderate Buy
11 Buy
5 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$387.47
▲(19.94% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $387.47 with a high forecast of $435.00 and a low forecast of $331.00. The average price target represents a 19.94% change from the last price of $323.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"269":"$269","436":"$436","310.75":"$310.8","352.5":"$352.5","394.25":"$394.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$435.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":387.46666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$387.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":331,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$331.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[269,310.75,352.5,394.25,436],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,372.68,377.4738461538462,382.2676923076923,387.0615384615385,391.8553846153846,396.64923076923077,401.44307692307694,406.23692307692306,411.03076923076924,415.8246153846154,420.61846153846153,425.4123076923077,430.2061538461538,{"y":435,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,372.68,373.8174358974359,374.9548717948718,376.0923076923077,377.2297435897436,378.3671794871795,379.50461538461536,380.6420512820513,381.77948717948715,382.91692307692307,384.05435897435893,385.19179487179485,386.3292307692307,{"y":387.46666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,372.68,369.4738461538462,366.2676923076923,363.0615384615385,359.8553846153846,356.64923076923077,353.44307692307694,350.23692307692306,347.03076923076924,343.8246153846154,340.61846153846153,337.4123076923077,334.2061538461538,{"y":331,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":399.774,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":369.167,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.194,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":270.103,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.363,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.926,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":348.402,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":339.735,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":292.268,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":372.68,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$435.00Average Price Target$387.47Lowest Price Target$331.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on ELV
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$345→$360
Hold
11.44%
Upside
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Entrada Therapeutics Inc (NASDAQ: TRDA), Edgewise Therapeutics (NASDAQ: EWTX) and Elevance Health (NYSE: ELV)
Bank of America Securities Analyst forecast on ELV
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$425→$435
Buy
34.65%
Upside
Upgraded
04/29/26
Elevance Health upgraded to Buy from Neutral at BofAElevance Health upgraded to Buy from Neutral at BofA
J.P. Morgan Analyst forecast on ELV
Lisa Gill
J.P. Morgan
J.P. Morgan
$397→$411
Buy
27.22%
Upside
Assigned
04/28/26
Elevance Health price target raised to $411 from $397 at JPMorganElevance Health price target raised to $411 from $397 at JPMorgan
Mizuho Securities Analyst forecast on ELV
Ann Hynes
Mizuho Securities
Mizuho Securities
$350→$385
Buy
19.18%
Upside
Reiterated
04/27/26
Mizuho Securities Sticks to Their Buy Rating for Elevance Health (ELV)
Goldman Sachs Analyst forecast on ELV
Scott Fidel
Goldman Sachs
Goldman Sachs
$350→$370
Hold
14.53%
Upside
Reiterated
04/24/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Elevance Health (NYSE: ELV) and Eli Lilly & Co (NYSE: LLY)
Bernstein Analyst forecast on ELV
Lance Wilkes
Bernstein
Bernstein
$384→$424
Buy
31.25%
Upside
Reiterated
04/24/26
Bernstein Remains a Buy on Elevance Health (ELV)
TD Cowen Analyst forecast on ELV
Ryan Langston
TD Cowen
TD Cowen
$400
Buy
23.82%
Upside
Reiterated
04/24/26
Elevance Health: Strong Earnings Momentum and Attractive Valuation Support Buy Rating and $400 Target
Truist Financial Analyst forecast on ELV
David S Macdonald
Truist Financial
Truist Financial
―
Buy
―
Reiterated
04/23/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (NYSE: ELV), Medpace Holdings (NASDAQ: MEDP) and Cytokinetics (NASDAQ: CYTK)
Leerink Partners Analyst forecast on ELV
Whit Mayo
Leerink Partners
Leerink Partners
$357→$364
Hold
12.68%
Upside
Reiterated
04/23/26
Elevance Health price target raised to $364 from $357 at LeerinkElevance Health price target raised to $364 from $357 at Leerink
Wells Fargo Analyst forecast on ELV
Stephen Baxter
Wells Fargo
Wells Fargo
$391
Buy
21.03%
Upside
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (NYSE: WST), Molina Healthcare (NYSE: MOH) and Elevance Health (NYSE: ELV)
Guggenheim Analyst forecast on ELV
Jason Cassorla
Guggenheim
Guggenheim
$396→$399
Buy
23.51%
Upside
Reiterated
04/23/26
Guggenheim Remains a Buy on Elevance Health (ELV)
Robert W. Baird Analyst forecast on ELV
Michael Ha
Robert W. Baird
Robert W. Baird
$317→$331
Hold
2.46%
Upside
Reiterated
04/23/26
Elevance Health price target raised to $331 from $317 at BairdElevance Health price target raised to $331 from $317 at Baird
Barclays Analyst forecast on ELV
Andrew Mok CFA
Barclays
Barclays
$393
Buy
21.65%
Upside
Reiterated
04/23/26
Barclays Sticks to Its Buy Rating for Elevance Health (ELV)
RBC Capital Analyst forecast on ELV
Ben Hendrix
RBC Capital
RBC Capital
$358
Hold
10.82%
Upside
Reiterated
04/22/26
Elevance Health (ELV) Gets a Hold from RBC Capital
Jefferies Analyst forecast on ELV
David Windley
Jefferies
Jefferies
$391
Buy
21.03%
Upside
Reiterated
04/20/26
Jefferies Remains a Buy on Elevance Health (ELV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on ELV
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$345→$360
Hold
11.44%
Upside
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Entrada Therapeutics Inc (NASDAQ: TRDA), Edgewise Therapeutics (NASDAQ: EWTX) and Elevance Health (NYSE: ELV)
Bank of America Securities Analyst forecast on ELV
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$425→$435
Buy
34.65%
Upside
Upgraded
04/29/26
Elevance Health upgraded to Buy from Neutral at BofAElevance Health upgraded to Buy from Neutral at BofA
J.P. Morgan Analyst forecast on ELV
Lisa Gill
J.P. Morgan
J.P. Morgan
$397→$411
Buy
27.22%
Upside
Assigned
04/28/26
Elevance Health price target raised to $411 from $397 at JPMorganElevance Health price target raised to $411 from $397 at JPMorgan
Mizuho Securities Analyst forecast on ELV
Ann Hynes
Mizuho Securities
Mizuho Securities
$350→$385
Buy
19.18%
Upside
Reiterated
04/27/26
Mizuho Securities Sticks to Their Buy Rating for Elevance Health (ELV)
Goldman Sachs Analyst forecast on ELV
Scott Fidel
Goldman Sachs
Goldman Sachs
$350→$370
Hold
14.53%
Upside
Reiterated
04/24/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Elevance Health (NYSE: ELV) and Eli Lilly & Co (NYSE: LLY)
Bernstein Analyst forecast on ELV
Lance Wilkes
Bernstein
Bernstein
$384→$424
Buy
31.25%
Upside
Reiterated
04/24/26
Bernstein Remains a Buy on Elevance Health (ELV)
TD Cowen Analyst forecast on ELV
Ryan Langston
TD Cowen
TD Cowen
$400
Buy
23.82%
Upside
Reiterated
04/24/26
Elevance Health: Strong Earnings Momentum and Attractive Valuation Support Buy Rating and $400 Target
Truist Financial Analyst forecast on ELV
David S Macdonald
Truist Financial
Truist Financial
―
Buy
―
Reiterated
04/23/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (NYSE: ELV), Medpace Holdings (NASDAQ: MEDP) and Cytokinetics (NASDAQ: CYTK)
Leerink Partners Analyst forecast on ELV
Whit Mayo
Leerink Partners
Leerink Partners
$357→$364
Hold
12.68%
Upside
Reiterated
04/23/26
Elevance Health price target raised to $364 from $357 at LeerinkElevance Health price target raised to $364 from $357 at Leerink
Wells Fargo Analyst forecast on ELV
Stephen Baxter
Wells Fargo
Wells Fargo
$391
Buy
21.03%
Upside
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (NYSE: WST), Molina Healthcare (NYSE: MOH) and Elevance Health (NYSE: ELV)
Guggenheim Analyst forecast on ELV
Jason Cassorla
Guggenheim
Guggenheim
$396→$399
Buy
23.51%
Upside
Reiterated
04/23/26
Guggenheim Remains a Buy on Elevance Health (ELV)
Robert W. Baird Analyst forecast on ELV
Michael Ha
Robert W. Baird
Robert W. Baird
$317→$331
Hold
2.46%
Upside
Reiterated
04/23/26
Elevance Health price target raised to $331 from $317 at BairdElevance Health price target raised to $331 from $317 at Baird
Barclays Analyst forecast on ELV
Andrew Mok CFA
Barclays
Barclays
$393
Buy
21.65%
Upside
Reiterated
04/23/26
Barclays Sticks to Its Buy Rating for Elevance Health (ELV)
RBC Capital Analyst forecast on ELV
Ben Hendrix
RBC Capital
RBC Capital
$358
Hold
10.82%
Upside
Reiterated
04/22/26
Elevance Health (ELV) Gets a Hold from RBC Capital
Jefferies Analyst forecast on ELV
David Windley
Jefferies
Jefferies
$391
Buy
21.03%
Upside
Reiterated
04/20/26
Jefferies Remains a Buy on Elevance Health (ELV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months
xxx
Success Rate
11/16 ratings generated profit
69%
Average Return
+3.08%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +3.08% per trade.
1 Year
A.J. RiceUBS
Success Rate
24/31 ratings generated profit
77%
Average Return
+18.00%
Copying A.J. Rice's trades and holding each position for 1 Year would result in 77.42% of your transactions generating a profit, with an average return of +18.00% per trade.
2 Years
xxx
Success Rate
28/31 ratings generated profit
90%
Average Return
+40.26%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 90.32% of your transactions generating a profit, with an average return of +40.26% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
20
22
26
25
21
Hold
6
7
5
9
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
29
31
34
30
In the current month, ELV has received 21 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 387.47.
Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $6.20 with a range of $6.00 to $6.73. The previous quarter’s EPS was $12.58. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.
Next quarter’s earnings estimate for ELV is $6.20 with a range of $6.00 to $6.73. The previous quarter’s EPS was $12.58. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $48.77B with a range of $47.58B to $49.66B. The previous quarter’s sales results were $50.18B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.
Next quarter’s sales forecast for ELV is $48.77B with a range of $47.58B to $49.66B. The previous quarter’s sales results were $50.18B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Stock Forecast FAQ

What is ELV’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is 387.47.
    What is ELV’s upside potential, based on the analysts’ average price target?
    Elevance Health has 19.94% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ELV a Buy, Sell or Hold?
          Elevance Health has a consensus rating of Moderate Buy which is based on 11 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Elevance Health’s price target?
            The average price target for Elevance Health is 387.47. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $435.00 ,the lowest forecast is $331.00. The average price target represents 19.94% Increase from the current price of $323.05.
              What do analysts say about Elevance Health?
              Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of ELV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.